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Abstract
Background: Infection with Zika virus (ZIKV) during pregnancy is known to cause birth defects 
and could also be linked to pregnancy loss.
Case: A pregnant woman in Puerto Rico contracted ZIKV at 16 weeks gestation. ZIKV RNA 
persisted in serum from her initial test at 16 weeks through 24 weeks gestation, when fetal demise 
occurred, and was detected in placental tissue.
Conclusion: Prolonged detection of ZIKV RNA in maternal serum was associated with ZIKV 
RNA detection in the placenta of a patient who experienced fetal demise. While detection of 
placenta ZIKV RNA does not establish that ZIKV conclusively caused the demise, these findings 
support emerging evidence that the placenta may serve as a reservoir for ZIKV, which may be 
associated with prolonged detection of ZIKV RNA in serum.
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1. Introduction
Zika virus (ZIKV) is primarily transmitted by Aedes species mosquitoes, and is closely 
related to dengue, West Nile, and yellow fever viruses. Although most ZIKV infections are 
asymptomatic, those who do develop disease experience a mild illness characterized by rash, 
fever, arthralgia, myalgia, and/or non-purulent conjunctivitis. When first isolated in 1954 
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[1], ZIKV was reported to cause a mild illness without observed severe manifestations. Few 
human cases were identified over the subsequent 50 years until a ZIKV outbreak occurred in 
2007 in the Pacific island nation of Yap, Federated States of Micronesia [2]. Subsequent 
outbreaks occurred in French Polynesia during 2012–2013 [3] and in 2015 ZIKV spread to 
Brazil and throughout the Americas and the Caribbean [4] [5] [6]. After the emergence of 
ZIKV in Brazil, it was found that ZIKV causes birth defects in children congenitally 
infected and has been associated with other adverse pregnancy outcomes [7] [8] [9] [10]. 
Prolonged detection of ZIKV ribonucleic acid (RNA) has been observed among pregnant 
women [11]; however, the clinical significance of this finding has not been firmly 
established. Some have suggested that prolonged detection of viral RNA may be a marker of 
fetal infection and adverse pregnancy outcomes [7]. ZIKV infection early in pregnancy has 
been associated with prolonged detection of ZIKV RNA in serum and infectious virus was 
isolated from the mother’s placenta tissue and maternal serum in a pregnancy loss [12]. Case 
series of women infected with ZIKV during the first and second trimester demonstrated the 
presence of ZIKV in placental and fetal tissue, suggesting that ZIKV RNA can persist in 
these tissues [13] [14] [15].
The first locally acquired case of ZIKV infection in Puerto Rico was reported in December 
2015. Patients with symptomatic ZIKV disease were identified through passive surveillance, 
and in early 2016 the Puerto Rico Department of Health (PRDH), with assistance from the 
Centers for Disease Control and Prevention (CDC), implemented routine screening of 
pregnant women with RT-PCR to detect viral RNA and ELISA testing to detect anti-ZIKV 
IgM antibodies. By the end of 2017, over 4000 pregnant women were diagnosed with 
laboratory evidence of possible ZIKV infection [16].
Detection of ZIKV RNA by RT-PCR is possible in various body fluids, including serum, 
urine, saliva, semen, vaginal secretions, cerebrospinal fluid, and amniotic fluid [17] [18] [19] 
[20]. Clearance of ZIKV nucleic acid from serum is expected to occur in most non-pregnant 
individuals within two months of infection [3] [20]. However, several studies indicate that 
ZIKV RNA may be detectable for longer periods in pregnant women [11] [21]. Hypotheses 
as to why pregnant women may experience prolonged detection of ZIKV RNA include 
replication of ZIKV in the placenta, specifically in placental trophoblasts [22] [23] and 
Hofbauer cells (HBC) [24]. This finding led to the conclusion that transmission of ZIKV 
from mother to fetus is likely trans-placental, rather than during parturition [13] [22] [24], 
and suggests that viral replication in the placenta may precede fetal infection [13]. The 
mechanism and correlation of viral persistence in the placenta and detection in human serum 
is not known. This case report provides additional clinical information adding to the growing 
body of evidence that will elucidate the pathologic and clinical findings associated with 
maternal and congenital ZIKV infection.
2. Case
In May 2016, a 38 year-old nulliparous woman at approximately 16 weeks’ gestation sought 
care for a one-day history of fever, rash, myalgia, arthralgia, and headache. Her only 
significant medical history was well-controlled high blood pressure. Diagnostic testing for 
toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus, and human 
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immunodeficiency virus (HIV) (i.e., TORCH) performed at 10 weeks’ gestation was 
negative. At the time of her visit, the patient agreed to participate in an ongoing study of 
acute febrile illness, which collected blood, urine, and nasopharyngeal specimens for 
diagnostic testing [25].
ZIKV RNA was detected in serum by RT-PCR one day after symptom onset; serum IgM 
testing and urine RT-PCR were both negative. The patient was enrolled in the Zika virus 
Persistence study [20], for which serum, whole blood, urine, saliva, and vaginal secretions 
were collected weekly for 1 month and subsequently every 2 weeks thereafter. Collected 
serum specimens were tested for ZIKV, dengue virus, and chikungunya virus nucleic acid by 
RT-PCR [26], and for anti-ZIKV IgM and anti-dengue virus IgM and IgG antibodies by 
ELISA [20].
ZIKV RNA was detected in serum on days 1, 15, 22, 29, 36, 50 and 54 post illness onset 
(i.e., 18 – 24 weeks’ gestation) (Figure 1). The patient was referred to a maternal-fetal 
medicine (MFM) specialist at 20 weeks’ gestation due to a positive quadruple screen test, 
1:8 suggestive of Down syndrome, and a positive test for ZIKV infection. At approximately 
24 weeks’ gestation, a level II ultrasound demonstrated generalized edema predominantly 
localized to the upper portion of the fetus’ body, a small amount of ascites, a single 
umbilical artery, and the absence of cardiac activity consistent with fetal demise. The patient 
was admitted to a hospital the following day for labor induction. TORCH testing was 
repeated, testing was performed for Lupusanticoagulant, and urine and serum were screened 
for drug and toxins, all of which were negative. The fetus was delivered vaginally at 24 
weeks’ gestation in breech position approximately 8 hours after the initiation of labor 
induction. No cardiac or respiratory activity was present in the fetus at birth consistent with 
the diagnosis of fetal demise. Fetal weight was 3,289 grams. The fetus was edematous and 
macerated, and skin desquamation was present in the upper and lower extremities. The 
abdomen had skin discoloration suggestive of possible hematoma. Thinning of the umbilical 
cord at insertion site was noted. No dysmorphic features or neural tube defects were 
observed, and no clinical stigmata of Down’s syndrome were present. A retained placenta 
requiring a dilation and curettage complicated the mother’s clinical course. She recovered 
satisfactorily and was discharged home the following day. Parental consent was not provided 
for fetal autopsy; however, consent was given to examine the umbilical cord and placenta.
The placenta weighed 213 grams and measured 12 × 11.3 × 2.8 cm. The fetal and maternal 
membranes were well vascularized and the umbilical cord was inserted at the margin, 
measuring 23 × 1 cm, with two blood vessels present. The maternal surface had complete 
cotyledons, and transverse sections revealed spongy tan parenchyma. Upon microscopic 
evaluation, the placenta had patchy villous edema. Karyorrhectic debris was present around 
vessels within edematous villi, and larger sclerotic, avascular villi often had associated 
perivillous fibrin deposition. Stippled, deeply-basophilic calcifications were scattered within 
multiple villi. Multifocal aggregates of plasma cells were present within the decidua. 
Histologic findings were nonspecific, consistent with findings seen with intrauterine fetal 
demise and/or circulatory issues within the placenta, though the presence of plasma cells and 
other mononuclear cells within the decidua has been described as a sign of chronic antigenic 
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stimulation [27]. ZIKV RNA was detected by RT-PCR in a specimen of placenta; however, 
ZIKV antigen was not detected by immunohistochemistry.
The patient was followed as part the Zika Virus Persistence study protocol. RT-PCR testing 
did not detect ZIKV RNA at 64, 78, and 92 days post-illness onset (Figure 1). On day 120 
after illness onset, ZIKV RNA was detected at low levels in a serum specimen. All serum, 
urine, saliva and vaginal secretions collected thereafter were negative by RT-PCR. Anti-
ZIKV IgM antibody was first detected in serum on day 15 post-illness onset and was last 
detected on day 78 post-illness onset (Table 1). The same specimens were also tested by 
anti-DENV IgM ELISA, and all were negative. Anti-DENV IgG antibody was detected by 
ELISA in the specimen collected on the first day of acute febrile illness (week 16 gestation), 
demonstrating previous DENV infection. Further analysis of neutralizing antibodies by 
plaque reduction neutralization test (PRNT) on the same specimen [28] [29] demonstrated 
high titers against DENV−2, low titers to DENV−1, −3, and −4, and no titers against ZIKV, 
which together suggested prior infection with DENV−2. Specimens collected in the weeks 
following the initial infection demonstrated a robust neutralizing antibody response to ZIKV, 
including greater than 4-fold increase in titers against all DENVs, consistent with antibody 
response to secondary flavivirus infection [30].
3. Discussion
ZIKV infection has been shown to cause birth defects among children congenitally infected 
and is linked to other abnormal pregnancy outcomes [31], including pregnancy loss [12] [13] 
[14] [15]. In this case report, ZIKV RNA was detectable throughout pregnancy and only 
became non-detectable by RT-PCR following delivery of the fetal demise, and ZIKV nucleic 
acid was detected in placental tissue. These findings support the notion that the placenta is a 
potential site of infection and may serve as a reservoir of ZIKV RNA [13] [15] [22] [24] 
[32]. As an immunologically privileged site, it may take longer for maternal clearance of 
ZIKV RNA due to the down regulation of the maternal-fetal immune interface. The immune 
changes during pregnancy, which can allow pathogens to avoid clearance and be transmitted 
from the mother to the fetus, are not well understood but may involve the production of 
inhibitory cytokines (e.g., IL-35) by placental trophoblasts [33].
To date, the factors that predispose some pregnant women with ZIKV infection to adverse 
pregnancy outcomes and why others clear the infection without an effect on the fetus is not 
clear. Factors that may affect the likelihood of ad verse pregnancy outcomes are the timing 
of infection, viral load, and the maternal immune response. Infection during certain critical 
time points during pregnancy may allow for a blunted or heightened maternal immune 
response. Placental blood flow, initiated at approximately gestational week 10, may also 
affect risk of fetal infection and adverse outcomes [34]. This patient had evidence of acute 
infection at 16 weeks gestation, a time at which the maternal infection may already have 
resulted in fetal infection. Fetal immunity is just beginning to develop at this early stage of 
gestation; hence, clearance of the infection is reliant on the maternal immune response.
Interestingly, testing of maternal serum was repeatedly negative by RT-PCR between 64 and 
92 days post-onset of illness; however at day 120, a small amount of ZIKV RNA was 
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detected. The clinical significance of this finding is unclear, and false positive test results 
have been reported [35]. Of note, intermittent detection of ZIKV RNA has been reported in 
both pregnant and non-pregnant individuals [11] [20] [36]. Also, the positive RT-PCR on 
day 120 may not have represented active viral replication [37]. Similar observations of 
intermittent shedding of viral RNA have been observed for ebolavirus [38], HIV [39], and 
other flaviviruses (i.e., Japanese encephalitis virus, West Nile virus, and tick-borne 
encephalitis virus) [37]. Therefore, the isolated detection on day 120 after symptom onset 
could also suggest that the placenta or another tissue may have acted as a reservoir of and 
released fragments of viral nucleic acid into the serum.
This case demonstrates the importance of monitoring women infected with ZIKV during 
pregnancy and the need to counsel women of the potential risks of ZIKV infection during 
pregnancy. Limited data are available regarding the prolonged detection of ZIKV RNA 
among pregnant women; therefore assessing the association of pregnancy outcomes with 
prolonged detection of RNA will be important. Further, research is needed to conclusively 
determine if the placenta does indeed serve as a reservoir for ZIKV replication, and the 
mechanism by which the placenta regulates maternal-fetal transmission of infection. Last, 
establishing whether prolonged detection of ZIKV RNA in serum is a predictor of fetal 
demise or other adverse pregnancy outcomes will be important. Immunocompromised mice 
infected with ZIKV early in pregnancy demonstrate placental damage and fetal demise, and 
ZIKV RNA was detected in the placenta at levels ~1000-fold higher than in maternal serum 
[23]. If the same occurs in humans, we could infer that high levels of ZIKV RNA in serum 
may have the potential to serve as a marker for placental infection and higher placenta viral 
loads.
Repeat testing of women with an established diagnosis of ZIKV infection is not currently 
recommended for monitoring pregnant women exposed to ZIKV since the clinical 
significance of the findings is unknown [40]. Additional research is needed to determine the 
clinical value of such repeat testing, and to assess if repeat testing by RT-PCR in ZIKV-
positive pregnant women can predict adverse pregnancy or fetal outcomes or pregnancy loss.
4. Conclusion
Upon physical examination of the fetus, no dysmorphic features were observed and no 
clinical stigmata of Down’s syndrome were present. However, since autopsy of the fetus 
could not be performed due to lack of parental consent, Down syndrome could not be 
completely ruled out. Nonetheless, more research is needed to establish what the risk of 
pregnancy loss is for women infected with ZIKV during pregnancy and to understand the 
role of persistent viremia in these outcomes.
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Figure 1. 
Detection of Zika virus nucleic acid in serum specimens from an infected pregnant woman, 
Puerto Rico, 2016.
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Table 1.
Detection of anti-Zika virus IgM antibody and neutralizing antibody titers against Zika virus and the four 
dengue virus types in a pregnant woman infected with Zika virus, Puerto Rico, 2016.
Plaque Reduction Neutralization Test (PRNT)
Days Post Onset of Symptoms Anti-ZIKV IgM ELISA ZIKV DENV-1 DENV-2 DENV-3 DENV-4
0 Neg <10 20 640 40 40
15 Pos 5120 2560 >20,480 2560 320
22 Pos 5120 2560 >20,480 2560 160
29 Pos 5120 1280 ≥20,480 640 160
36 Pos 5120 320 20,480 640 320
50 Pos 5120 640 20,480 640 160
54 ND 10,240 320 10,240 640 160
64 Pos ND ND ND ND ND
78 Pos ND ND ND ND ND
92 Neg ND ND ND ND ND
120 Neg ND ND ND ND ND
137 Neg ND ND ND ND ND
151 Neg ND ND ND ND ND
165 Neg ND ND ND ND ND
179 Neg ND ND ND ND ND
Abbreviations: ZIKV = Zika virus; DENV = dengue virus, ND = not done.
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